Siemens Healthineers radiation therapy unit Varian has received an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) for a new clinical trial evaluating its Flash therapy technology.
Building on clinical evidence from the initial FeAsibility Study of Flash therapy for the Treatment of Symptomatic Bone Metastases (FAST-01) clinical trial, FAST-02 will include bone metastases in the chest, according to Varian.
The trial, which will be conducted at Cincinnati Children's/UC Health Proton Therapy Center, is expected to enroll 10 patients with painful thoracic bone metastases. Led by principal investigator Dr. John Breneman, the researchers will assess treatment-related side effects and treatment efficacy, Varian said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
